HPV阴性口咽癌经口微创手术的结局
回顾性队列研究纳入89例接受原发经口手术的HPV阴性口咽鳞癌患者,3年总生存率为67.2%、无复发生存率为63.3%,晚期肿瘤分期与更差生存相关,1年胃造瘘管依赖率6%、气管切开依赖率3%。
要点
- HPV阴性口咽癌经口手术3年OS为67.2%、RFS为63.3%。
- 晚期肿瘤分期预测更差OS(HR 3.23)和RFS(HR 2.38)。
- 1年胃造瘘管依赖率6%、气管切开依赖率3%。
核心结论
- 经口手术可作为HPV阴性口咽鳞癌的原发治疗选择,肿瘤学结局可接受且可能改善功能结局。
研究设计与样本
- 回顾性队列研究,纳入1998至2020年接受原发根治性经口手术联合风险适配辅助治疗的HPV阴性口咽鳞癌患者89例。
主要发现
- 全队列3年总生存率估计为67.2%,无复发生存率估计为63.3%。
- 单变量分析中晚期肿瘤分期预测更差OS(HR 3.23,95%CI 1.75-5.95)和RFS(HR 2.38,95%CI 1.13-5.01)。
- III/IV期疾病与更差OS相关(HR 2.16,95%CI 1.01-4.63),但与RFS无关。
- 1年时5例(6%)依赖胃造瘘管、3例(3%)依赖气管切开。
关键数值与推荐
- 多数患者为晚期疾病(III/IV期占73%),79%为早期肿瘤分期(T1/T2),71%有阳性淋巴结。
临床怎么用
- 对于HPV阴性口咽鳞癌,经口手术可作为原发治疗方案,需结合肿瘤分期评估生存与功能获益。
局限性
- 回顾性设计,样本量89例,单中心高容量NCI指定机构数据,结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To describe the clinical predictors of survival, disease control, and functional outcomes in patients with HPV-negative oropharyngeal squamous cell carcinoma (OPSCC) who underwent primary transoral surgery (TOS). STUDY DESIGN: Retrospective cohort study. SETTING: The study was conducted in a high-volume, NCI-designated tertiary care setting. METHODS: Patients with HPV-negative OPSCC who underwent primary definitive TOS with risk-adapted adjuvant therapy (1998-2020) were identified. The primary outcome measures were overall survival (OS) and recurrence-free survival (RFS). Secondary outcomes included postoperative gastrostomy tube (G-tube) rates, tracheostomy rates, and functional outcome swallowing scale (FOSS) scores. RESULTS: A total of 89 patients were treated with TOS for HPV-negative OPSCC. The majority of patients presented with late-stage disease (stage III/IV, 73%); 79% with early tumor stage (T1/T2) and 71% with positive nodal disease. Three-year estimates for OS and RFS for the entire cohort were 67.2% and 63.3% respectively. Advanced tumor stage predicted worsened OS [HR 3.23, 95% CI 1.75-5.95] and RFS [HR 2.38, 95% CI 1.13-5.01] on univariable analysis. Stage III/IV disease was associated with worsened OS [HR 2.16, 95% CI 1.01-4.63], but not RFS. Thirty-two patients (36%) recurred during the follow-up period; 19 (21%) failed locoregionally, and 13 (15%) failed distantly. Five patients (6%) were G-tube dependent and 3 patients (3%) were tracheostomy dependent at 1-year. CONCLUSION: Transoral surgery may be considered as a primary treatment in HPV-negative OPSCC with acceptable oncologic outcomes and the potential for improved functional outcomes.
引用
- Chang KW, Peterson AM, Tharakan T, et al. Outcomes of Minimally Invasive Transoral Surgery in HPV-Negative Oropharyngeal Cancer. Otolaryngol Head Neck Surg. 2026. PMID: 41609367. doi:10.1002/ohn.70142
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。